Lupin's Alliance Partner Concord Receives U.S. FDA Approval for Tacrolimus Capsules USP

Pharma major Lupin Limited (Lupin) in alliance with Concord Biotech Limited (Concord) announced today that it has received approval from the United States Food and Drug Administration (U.S. FDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, to market a generic version of Prograf® Capsules, 0.5 mg, 1 mg, and 5 mg, of Astellas Pharma US, Inc.

Tacrolimus Capsules USP are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney or heart transplants, in combination with other immunosuppressants.

Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg (RLD: Prograf®) had an annual sales of approximately USD 303 million in the U.S. (IQVIA MAT September 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.911 as compared to the previous close of Rs. 858.85. The total number of shares traded during the day was 510531 in over 17189 trades.

The stock hit an intraday high of Rs. 913.35 and intraday low of 863. The net turnover during the day was Rs. 457058462.

Source : Equity Bulls

Keywords